Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vesicare
Drug ID BADD_D02353
Description Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511]
Indications and Usage For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Marketing Status Prescription
ATC Code G04BD08
DrugBank ID DB01591
KEGG ID D01269
MeSH ID D000069464
PubChem ID 154058
TTD Drug ID D0L4YD
NDC Product Code Not Available
Brand Not Available
Synonym Solifenacin Succinate | Succinate, Solifenacin | Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate | YM905 | YM 905 | 905, YM | Vesicare | Solifenacin | 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-
Chemical Information
Molecular Formula C23H27ClN2O2
CAS Registry Number 180468-39-7
SMILES C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Bladder pain20.02.02.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Cystitis20.03.02.002; 11.01.14.001--
Delirium19.13.02.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug interaction08.06.03.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dry throat22.02.05.004; 07.06.01.005--Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphonia17.02.08.004; 22.02.05.005; 19.19.03.002--
Dysuria20.02.02.002--
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Food interaction08.06.03.002--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages